Aliases & Classifications for Critical Limb Ischemia

MalaCards integrated aliases for Critical Limb Ischemia:

Name: Critical Limb Ischemia 39 56 74
Cli 56

External Ids:

UMLS 74 C1142264

Summaries for Critical Limb Ischemia

MalaCards based summary : Critical Limb Ischemia, also known as cli, is related to peripheral artery disease and peripheral vascular disease. An important gene associated with Critical Limb Ischemia is HGF (Hepatocyte Growth Factor), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Aspirin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Critical Limb Ischemia

Diseases related to Critical Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 30.9 IL6 VEGFA
2 peripheral vascular disease 30.8 IL6 VEGFA VWF
3 limb ischemia 30.6 HGF IL6 TEK TNF VEGFA VWF
4 intermittent claudication 30.4 IL6 VEGFA VWF
5 arteries, anomalies of 30.4 IL6 TNF VEGFA VWF
6 burns 30.4 HGF TNF
7 arteriosclerosis obliterans 30.2 HGF IL6
8 vascular disease 29.2 F5 IL6 TNF VEGFA VWF
9 ischemia 11.4
10 diabetes mellitus 10.3
11 wrinkles 10.3 HGF VEGFA
12 carpal tunnel syndrome 10.3 IL6 VEGFA
13 buerger disease 10.3
14 end stage renal failure 10.3
15 spinal disease 10.3 IL6 VEGFA
16 blood group, globoside system 10.3 IL6 VEGFA
17 primary effusion lymphoma 10.3 IL6 VEGFA
18 macular retinal edema 10.2 IL6 VEGFA
19 adult respiratory distress syndrome 10.2 IL6 TNF
20 bronchiolitis obliterans 10.2 IL6 TNF
21 dengue hemorrhagic fever 10.2 IL6 TNF
22 autoimmune disease of musculoskeletal system 10.2 IL6 TNF
23 tonsillitis 10.2 IL6 TNF
24 filariasis 10.2 IL6 TNF
25 parasitic protozoa infectious disease 10.2 IL6 TNF
26 human immunodeficiency virus infectious disease 10.2 IL6 TNF
27 coronary stenosis 10.2 IL6 VWF
28 scorpion envenomation 10.2 IL6 TNF
29 leukomalacia 10.2 IL6 TNF
30 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
31 autoimmune myocarditis 10.2 IL6 TNF
32 streptococcal toxic-shock syndrome 10.2 IL6 TNF
33 juvenile ankylosing spondylitis 10.2 IL6 TNF
34 cardiogenic shock 10.2 IL6 TNF
35 null-cell leukemia 10.2 IL6 TNF
36 retinitis pigmentosa 55 10.2 IL6 TNF
37 glossitis 10.2 IL6 TNF
38 laryngitis 10.2 IL6 TNF
39 castleman disease 10.2 IL6 VEGFA
40 acute vascular insufficiency of intestine 10.2 IL6 TNF
41 posterior urethral valves 10.2 IL6 TNF
42 periapical periodontitis 10.2 IL6 TNF
43 autoimmune gastritis 10.2 IL6 TNF
44 meconium aspiration syndrome 10.2 IL6 TNF
45 burning mouth syndrome 10.2 IL6 TNF
46 central nervous system vasculitis 10.2 IL6 TNF
47 stachybotrys chartarum 10.2 IL6 TNF
48 louse-borne relapsing fever 10.2 IL6 TNF
49 endometrial disease 10.2 IL6 TNF
50 listeriosis 10.2 IL6 TNF

Graphical network of the top 20 diseases related to Critical Limb Ischemia:



Diseases related to Critical Limb Ischemia

Symptoms & Phenotypes for Critical Limb Ischemia

MGI Mouse Phenotypes related to Critical Limb Ischemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 F5 HGF IL6 TEK TNF VEGFA
2 hematopoietic system MP:0005397 9.73 HGF IL6 TEK TNF VEGFA VWF
3 embryo MP:0005380 9.72 F5 HGF TEK TNF VEGFA
4 liver/biliary system MP:0005370 9.55 F5 HGF IL6 TNF VEGFA
5 mortality/aging MP:0010768 9.5 F5 HGF IL6 TEK TNF VEGFA
6 nervous system MP:0003631 9.1 F5 IL6 TEK TNF VEGFA VWF

Drugs & Therapeutics for Critical Limb Ischemia

Drugs for Critical Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-78-2 2244
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 33069-62-4 36314
3
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 9005-49-6 46507594 772
4
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1 120202-66-6, 113665-84-2 60606
5
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2 73963-72-1 2754
6
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 5280723 149351
7
Menthol Approved Phase 4 2216-51-5 16666
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
10
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
11
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
12
Dalteparin Approved Phase 4,Phase 2 9005-49-6
13
Defibrotide Approved, Investigational Phase 4 83712-60-1
14
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
15
Calcium Approved, Nutraceutical Phase 4,Early Phase 1,Not Applicable 7440-70-2 271
16 Blood Substitutes Phase 4,Phase 2
17 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 3,Not Applicable
18 Vasodilator Agents Phase 4,Phase 3,Phase 2
19 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Autonomic Agents Phase 4,Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
23 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 calcium heparin Phase 4,Phase 1,Phase 2,Not Applicable
25 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
27 Antipyretics Phase 4,Phase 3,Phase 2
28 Antirheumatic Agents Phase 4,Phase 3,Phase 2
29 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
30 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
31 Phosphodiesterase Inhibitors Phase 4,Phase 3
32 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
33 Neuroprotective Agents Phase 4,Phase 3
34 Purinergic P2Y Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
35 Purinergic P2 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
36 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Bronchodilator Agents Phase 4,Phase 3,Phase 2
38 Phosphodiesterase 3 Inhibitors Phase 4,Phase 3
39 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
41 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Antipruritics Phase 4
43 Dermatologic Agents Phase 4
44 Antineoplastic Agents, Hormonal Phase 4,Phase 2
45 Hormone Antagonists Phase 4,Phase 2
46 Antiemetics Phase 4,Phase 2
47 glucocorticoids Phase 4,Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
49 Dexamethasone 21-phosphate Phase 4,Phase 2
50 Gastrointestinal Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
2 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
3 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
4 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
5 Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery Unknown status NCT01147419 Phase 4
6 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
7 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation Completed NCT01558505 Phase 4
8 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4
9 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE) Completed NCT00883246 Phase 4
10 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV Completed NCT00596752 Phase 4 Alprostadil
11 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
12 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
13 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
14 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
15 Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
16 Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial Completed NCT01389375 Phase 4
17 Peripheral Vascular Disease and Nerve Stimulation Completed NCT01942941 Phase 4
18 Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb) Completed NCT01718288 Phase 4 iloprost;Standard Treatment (aspirin.....),
19 DURABILITY+ : a Prospective, Multi-center, Controlled Study With the Everflex+ Stent in SFA Lesions Completed NCT01412463 Phase 4
20 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Recruiting NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
21 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Recruiting NCT02807779 Phase 4 Dexamethasone infusion
22 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
23 Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia Terminated NCT00403780 Phase 4 pregabalin;placebo
24 Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System Unknown status NCT02538978 Phase 3
25 Use of Indocyanine Green Angiography in Critical Limb Ischemia Unknown status NCT02820467 Phase 3
26 VADOplex Critical Limb Ischemia Study Unknown status NCT02034539 Phase 2, Phase 3
27 Distal Venous Arterialisation of Ischemic Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
28 Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia Unknown status NCT00434616 Phase 2, Phase 3
29 Pain and Music Therapy in Patients Suffering Arteritis Unknown status NCT01323504 Phase 3
30 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Unknown status NCT00539266 Phase 2, Phase 3
31 Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Unknown status NCT00132743 Phase 3 Cilostazol
32 Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
33 An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) Completed NCT01483898 Phase 3
34 Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI) Completed NCT01245335 Phase 3
35 Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions Completed NCT00566657 Phase 3
36 Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA) Completed NCT02454231 Phase 2, Phase 3
37 Bone Marrow Autograft in Limb Ischemia Completed NCT00904501 Phase 3
38 Drug Eluting Stents In The Critically Ischemic Lower Leg 2 Completed NCT01442636 Phase 2, Phase 3
39 Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries Completed NCT01630070 Phase 2, Phase 3
40 Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures Completed NCT00041925 Phase 2, Phase 3 CGT003 (E2F Duplex Decoy)
41 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed NCT00032487 Phase 3 Insulin;Glimepiride;Rosiglitazone;Metformin
42 Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease Completed NCT00059657 Phase 3 Ecraprost in lipid emulsion
43 Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Recruiting NCT03006770 Phase 3
44 The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia Recruiting NCT03551496 Phase 3
45 Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI) Recruiting NCT03423732 Phase 2, Phase 3 CardioCell;Placebos
46 Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia Recruiting NCT02230527 Phase 2, Phase 3 Ticagrelor;Clopidogrel
47 The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Recruiting NCT03174522 Phase 3 REX-001;Placebo
48 The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Recruiting NCT03111238 Phase 3 REX-001;Placebo
49 Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD Recruiting NCT02798913 Phase 3 Short DAPT;Long DAPT
50 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies Recruiting NCT03126968 Phase 2, Phase 3 Topical epinephrine;Placebos

Search NIH Clinical Center for Critical Limb Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Critical Limb Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Critical Limb Ischemia:
ACP-01, autologous angiogenic precursor cells for critical limb ischemia
ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
Autologous CD133+ cells for treatment of critical limb ischemia
Autologous endothelial progenitor cells for the treatment of critical limb ischemia
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for critical limb ischemia
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
Bone marrow-derived stem cells for treatment of diabetic foot ulcers
Enriched bone marrow-derived progenitor cells for ischemic diseases
ERCs, endometrial regenerative cells for critical limb ischemia
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
Mesendo, stem cell combination for treatment of limb ischemia
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
PDA002, Placenta-derived cells for vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
ReN009, human neural stem cells for peripheral arterial disease
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
StempeucelCLI, mesenchymal stem cells for vascular diseases
Umbilical cord blood stem cells for treatment of critical limb ischemia
Embryonic/Adult Cultured Cells Related to Critical Limb Ischemia:
Angiogenic cell precursors
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 9020076 23192920 22163120
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Bone marrow-derived mononuclear cells (family) PMIDs: 23586040 17394441 21216483
Peripheral blood-derived endothelial progenitor cells (family)
Peripheral blood-derived endothelial cells PMIDs: 19448678 18388019
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 22019148 19500466 19896796 18351022
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Tissue repair cells PMIDs: 23586040 17394441
Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
Bone marrow-derived progenitor cells
Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
Bone marrow-derived mononuclear cells PMIDs: 21586448
Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
MultiGeneAngio, transduced vein-derived endothelial cells
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived smooth muscle
Genetically modified vein-derived endothelial cells
Placenta-derived cells
Peripheral blood-derived hematopoietic stem cells
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
Neural stem cell line (CTX0E03) PMIDs: 23067568
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel�) PMIDs: 23307180 18720444 22731756
Umbilical cord blood-derived hematopoietic stem cells (family)

Genetic Tests for Critical Limb Ischemia

Anatomical Context for Critical Limb Ischemia

MalaCards organs/tissues related to Critical Limb Ischemia:

42
Bone, Bone Marrow, Endothelial, Skin, Spinal Cord, Smooth Muscle, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Critical Limb Ischemia:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
3 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Critical Limb Ischemia

Articles related to Critical Limb Ischemia:

(show top 50) (show all 1372)
# Title Authors Year
1
Re: "Is There an Important Role for Anxiety and Depression in the Elderly Patient with Critical Limb Ischemia, Especially after Major Amputation?" ( 30926421 )
2019
2
Is There an Important Role for Anxiety and Depression in the Elderly Patients with Critical Limb Ischemia, Especially After Major Amputation? ( 30731224 )
2019
3
Upper extremity distal dual bypass enables arteriovenous fistula construction in a critical limb ischemia. ( 30788100 )
2019
4
Comparison of open and endovascular procedures in patients with critical limb ischemia on dialysis. ( 30922740 )
2019
5
A prognostic score for clinical success after revascularization of critical limb ischemia in hemodialysis patients. ( 30922745 )
2019
6
Cost-effectiveness of the treatments for critical limb ischemia in the elderly population. ( 30922757 )
2019
7
Effectiveness of umbilical cord mesenchymal stem cells in patients with critical limb ischemia. ( 30926157 )
2019
8
2016 JAPAN Critical Limb Ischemia Database (JCLIMB) Annual Report. ( 30931073 )
2019
9
Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study. ( 30931726 )
2019
10
Cell therapy of critical limb ischemia-problems and prospects. ( 30969159 )
2019
11
One-year outcome of the everolimus eluting, balloon expandable Promus Element and Promus Element Plus stent in the treatment of below-the-knee lesions in patients with critical limb ischemia. ( 30994307 )
2019
12
Lower extremity critical limb ischemia: A review of clinical features and management. ( 31005554 )
2019
13
Critical limb ischemia in a patient with systemic lupus erythematosus: a case report. ( 31018871 )
2019
14
A network meta-analysis of randomized controlled trials comparing treatment modalities for infrapopliteal lesions in critical limb ischemia. ( 31075473 )
2019
15
The role of delirium and other risk factors on mortality in elderly patients with critical limb ischemia undergoing major lower limb amputation. ( 31077770 )
2019
16
Graft flow predictive equation in distal bypass grafting for critical limb ischemia. ( 31078341 )
2019
17
The Impact of Maternal Fructose Exposure on Angiogenic Activity of Endothelial Progenitor Cells and Blood Flow Recovery After Critical Limb Ischemia in Rat Offspring. ( 31100865 )
2019
18
Hyperbaric oxygen facilitates the effect of endothelial progenitor cell therapy on improving outcome of rat critical limb ischemia. ( 31105810 )
2019
19
Regarding: "Homemade Device to Facilitate Percutaneous Venous Arterialization in Patients With No-Option Critical Limb Ischemia". ( 31106690 )
2019
20
Impact of infection severity on clinical outcomes in critical limb ischemia with tissue loss after endovascular treatment. ( 29967952 )
2019
21
Comparison of the Cost of Drug-Eluting Stents versus Bare Metal Stents in the Treatment of Critical Limb Ischemia in the United States. ( 30092444 )
2019
22
Evaluation of the BASIL Survival Prediction Model in Patients Undergoing Infrapopliteal Interventions for Critical Limb Ischemia. ( 30099169 )
2019
23
Clinical Effects of Planned Endovascular Therapy for Critical Limb Ischemia Patients with Tissue Loss. ( 30135330 )
2019
24
Utility of indigo carmine angiography in patients with critical limb ischemia: Prospective multi-center intervention study (DIESEL-study). ( 30144339 )
2019
25
The impact of chronic kidney disease on lower extremity bypass outcomes in patients with critical limb ischemia. ( 30154013 )
2019
26
Functional prognosis of critical limb ischemia and efficacy of restoration of direct flow below the ankle. ( 30193553 )
2019
27
Safety and Effectiveness of Retrograde Arterial Access for Endovascular Treatment of Critical Limb Ischemia. ( 30217705 )
2019
28
Outcomes after Lower Extremity Revascularization for Treatment of Critical Limb Ischemia with Tissue Loss in Patients with Chronic Immune-Mediated Inflammatory Disease. ( 30217708 )
2019
29
Awareness of Scleroderma Peripheral Artery Disease Presenting With Critical Limb Ischemia in Elderly Patients. ( 30270312 )
2019
30
Objective Performance Goals for Surgical Treatment of Critical Limb Ischemia. ( 30287288 )
2019
31
A Comparison of Outcomes After Lower Extremity Bypass and Repeat Endovascular Intervention Following Failed Previous Endovascular Intervention for Critical Limb Ischemia. ( 30376723 )
2019
32
Alprostadil treatment of critical limb ischemia in hemodialysis patients : A retrospective single-center analysis. ( 30421286 )
2019
33
Urgent need to clarify the definition of chronic critical limb ischemia - a position paper from the European Society for Vascular Medicine. ( 30451092 )
2019
34
Endovascular Therapy Using Diluted Contrast Medium for Critical Limb Ischemia in a Patient with Chronic Kidney Disease. ( 30464136 )
2019
35
SCAI 2018 Think Tank Proceedings: "What skillsets are required of vascular interventional cardiologists in evaluating and managing critical limb ischemia (CLI)? What role should SCAI play in supporting interventional cardiologists in their CLI practices, individually and collectively?" ( 30489007 )
2019
36
Evaluation of Quiescent-Interval Single-Shot Magnetic Resonance Angiography in Diabetic Patients With Critical Limb Ischemia Undergoing Digital Subtraction Angiography: Comparison With Contrast-Enhanced Magnetic Resonance Angiography With Calf Compression at 3.0 Tesla. ( 30580695 )
2019
37
Peroneal bypass versus endovascular peroneal intervention for critical limb ischemia. ( 30580779 )
2019
38
Hybrid Foot Vein Arterialization in No-Option Patients With Critical Limb Ischemia: A Preliminary Report. ( 30591004 )
2019
39
Endovascular treatment of TransAtlantic Inter-Society Consensus II D femoropopliteal lesions in patients with critical limb ischemia. ( 30611581 )
2019
40
Six-Month Freedom From Amputation Rates and Quality of Life Following Tibial and Pedal Endovascular Revascularization for Critical Limb Ischemia. ( 30618346 )
2019
41
Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option critical limb ischemia. ( 30635050 )
2019
42
Critical limb ischemia: Current and novel therapeutic strategies. ( 30637723 )
2019
43
Plasma NAP-2 levels are associated with critical limb ischemia in peripheral arterial disease patients. ( 30638058 )
2019
44
Management of Non-Reconstructable Critical Limb Ischemia. ( 30664225 )
2019
45
Multidisciplinary Care for Critical Limb Ischemia: Current Gaps and Opportunities for Improvement. ( 30706755 )
2019
46
Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-Derived Mononuclear Cells Implantation in Critical Limb Ischemia With Scleroderma - Subanalysis of the Long-Term Clinical Outcomes Survey. ( 30726805 )
2019
47
Risk factors for critical limb ischemia in patients undergoing femoral cannulation for venoarterial extracorporeal membrane oxygenation: Is distal limb perfusion a mandatory approach? ( 30736721 )
2019
48
Six-Month Angiographic and Clinical Outcomes of Therapeutic Ultrasound Pretreatment Associated With Plain Balloon Angioplasty for Below-the-Knee Lesions in Patients With Critical Limb Ischemia: A Prospective, Single-Center Pilot Study. ( 30741077 )
2019
49
Relation between serum cotinine levels and trophic lesions in patients with critical limb ischemia: a pilot study. ( 30741123 )
2019
50
Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia. ( 30762155 )
2019

Variations for Critical Limb Ischemia

Expression for Critical Limb Ischemia

Search GEO for disease gene expression data for Critical Limb Ischemia.

Pathways for Critical Limb Ischemia

Pathways related to Critical Limb Ischemia according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 HGF IL6 TEK TNF VEGFA VWF
2
Show member pathways
13.26 HGF IL6 TEK TNF VEGFA
3
Show member pathways
13.23 HGF TEK TNF VEGFA VWF
4
Show member pathways
13.01 F5 HGF TEK VEGFA VWF
5
Show member pathways
12.96 HGF IL6 TEK TNF VEGFA
6
Show member pathways
12.84 HGF IL6 TEK TNF VEGFA VWF
7 12.49 HGF TEK TNF VEGFA
8
Show member pathways
12.38 IL6 TEK TNF
9 12.08 HGF TNF VEGFA
10
Show member pathways
12.06 HGF IL6 TNF
11 11.97 IL6 TNF VEGFA
12 11.96 IL6 TNF VEGFA
13
Show member pathways
11.94 HGF IL6 TEK TNF VEGFA VWF
14 11.85 HGF IL6 VEGFA
15 11.67 IL6 TEK VEGFA
16 11.65 IL6 TNF VEGFA
17 11.58 HGF TEK VWF
18 11.51 HGF IL6 TNF VEGFA
19 11.41 HGF IL6 TNF
20 11.39 IL6 VEGFA
21 11.39 IL6 TNF
22
Show member pathways
11.38 IL6 TNF VEGFA
23 11.36 IL6 TNF
24 11.34 IL6 TNF
25 11.34 TNF VEGFA
26 11.31 IL6 TNF
27
Show member pathways
11.27 HGF VEGFA
28 11.23 HGF IL6 TNF
29 11.22 IL6 TEK TNF VEGFA
30 11.21 IL6 TNF
31 11.19 IL6 TNF
32 11.18 HGF IL6 VEGFA
33 11.14 IL6 TNF
34 11.12 IL6 TNF
35 11.09 IL6 TNF
36 11 HGF IL6 TNF
37 10.99 TEK VEGFA
38 10.94 IL6 TNF
39 10.86 IL6 TNF
40 10.76 HGF IL6 TEK TNF

GO Terms for Critical Limb Ischemia

Cellular components related to Critical Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 F5 HGF IL6 TNF VEGFA
2 extracellular region GO:0005576 9.5 F5 HGF IL6 TEK TNF VEGFA
3 platelet alpha granule GO:0031091 9.16 F5 VWF
4 platelet alpha granule lumen GO:0031093 8.92 F5 HGF VEGFA VWF

Biological processes related to Critical Limb Ischemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.81 HGF IL6 TEK VEGFA
2 regulation of signaling receptor activity GO:0010469 9.78 HGF IL6 TNF VEGFA
3 MAPK cascade GO:0000165 9.76 HGF TEK TNF
4 positive regulation of protein kinase B signaling GO:0051897 9.71 HGF TEK TNF
5 positive regulation of angiogenesis GO:0045766 9.67 HGF TEK VEGFA
6 positive regulation of cell adhesion GO:0045785 9.62 TNF VEGFA
7 positive regulation of endothelial cell migration GO:0010595 9.62 TEK VEGFA
8 negative regulation of fat cell differentiation GO:0045599 9.61 IL6 TNF
9 positive chemotaxis GO:0050918 9.61 HGF VEGFA
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 HGF IL6 VEGFA
11 sprouting angiogenesis GO:0002040 9.6 TEK VEGFA
12 negative regulation of interleukin-6 production GO:0032715 9.59 HGF TNF
13 positive regulation of focal adhesion assembly GO:0051894 9.58 TEK VEGFA
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.58 IL6 TNF VEGFA
15 negative regulation of neurogenesis GO:0050768 9.57 IL6 TNF
16 positive regulation of protein complex assembly GO:0031334 9.56 TNF VEGFA
17 cytokine-mediated signaling pathway GO:0019221 9.56 HGF IL6 TNF VEGFA
18 positive regulation of chemokine production GO:0032722 9.55 IL6 TNF
19 positive regulation of glial cell proliferation GO:0060252 9.52 IL6 TNF
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.5 HGF TEK TNF
21 negative regulation of lipid storage GO:0010888 9.46 IL6 TNF
22 positive regulation of neuroinflammatory response GO:0150078 9.37 IL6 TNF
23 positive regulation of protein phosphorylation GO:0001934 9.26 HGF TEK TNF VEGFA
24 regulation of endothelial cell apoptotic process GO:2000351 9.16 TEK TNF
25 platelet degranulation GO:0002576 8.92 F5 HGF VEGFA VWF

Molecular functions related to Critical Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.16 HGF VEGFA
2 cytokine activity GO:0005125 9.13 IL6 TNF VEGFA
3 growth factor activity GO:0008083 8.8 HGF IL6 VEGFA

Sources for Critical Limb Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....